findmyKOL

Sarah Goglin, MD

Basic profile

San Francisco General Hospital

ORCIDNPI
RegionSan Francisco, CA · WestSpecialtyRheumatologyFocusRheumatology/Immunology
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Sarah Goglin is a Rheumatology/Immunology physician affiliated with San Francisco General Hospital. OpenAlex indexes 27 publications with 331 citations (h-index 8).

Overview

Scholarship

indexed output and impact (OpenAlex)
27publications

Distinct works indexed by OpenAlex, matched via ORCID.

331citations

Total citations across indexed works.

8h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

2 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    45.7%
    TNF inhibitor18.4%
    Enbrel Sureclick34%Enbrel32%Humira18%Humira Pen16%
    Part D<11 patients
    Folate Analog Metabolic Inhibitor16.4%
    Methotrexate82%Rasuvo18%
    Part D<11 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    23.7%
    Corticosteroid23.7%
    Prednisone100%
    Part D31 patients
  • Antiparasitic

    19.8%
    Antimalarial19.8%
    Hydroxychloroquine Sulfate100%
    Part D21 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”